Modern therapy of psoriasis from the point of view of systemic  inflammation: experience of using the drug Efleira

The article presents a modern view on the pathogenesis of psoriasis, considers an approach to management of patients with extensive moderate to severe psoriasis, sets out the key features of treatment with genetically engineered biological drugs of different groups: TNF-alpha, IL-17, IL-23 inhibitors. Literature data on the key features, indications, contraindications, and side effects associated with the use of genetically engineered drugs have also been analysed. The experience of using therapies described in domestic and foreign research publications was examined. Approaches to the treatment of patients with moderate to severe psoriasis combined with concomitant comorbid pathologies were discussed, and the features of treatment with genetically engineered biological drugs of different groups were also evaluated. In addition, the publication contains the results of our own observations obtained in the treatment of patients with extensive psoriasis and concomitant comorbid pathology using such biological drugs as secukinumab (10 patients), netakimab (5 patients), guselcumab (7 patients). The schemes of patient investigation, dosage regimens for each drug are given, their efficacy and tolerability are evaluated, and complications acquired during treatment with each drug are analysed, the speed and stability of the therapeutic effect provided by each of them are evaluated. In connection with the emergence of new data on the pathogenesis and treatment of psoriasis, patients have increasing opportunities to receive timely care, maintain disease remission for a long time and improve the quality of life regardless of the severity and stage of the pathological process, as well as of the history and presence of comorbid conditions.

show abstract

A modern view on the treatment of psoriatic disease. Experience in using genetically engineered biological therapy in patients with extensive moderate to severe psoriasis

Svechnikova

Zhufina

2022

Medicinskij sovet

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Modern therapy of psoriasis from the point of view of systemic inflammation: experience of using the drug Efleira

Cited by 1 publication

References 0 publications

A modern view on the treatment of psoriatic disease. Experience in using genetically engineered biological therapy in patients with extensive moderate to severe psoriasis

A modern view on the treatment of psoriatic disease. Experience in using genetically engineered biological therapy in patients with extensive moderate to severe psoriasis

Contact Info

Product

Resources

About